Yuli Hospital, Department of Health, Hualien, Taiwan.
Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan.
Neuropsychiatr Dis Treat. 2014 Sep 1;10:1629-34. doi: 10.2147/NDT.S67607. eCollection 2014.
Schizophrenia is a debilitating psychotic mental disorder that affects almost the entire range of human mental function. The devastating effect of the illness is usually long-lasting and requires lifelong treatment. Despite an evolved psychopharmacological understanding, the overall therapeutic effect of antipsychotics is still not satisfactory. The choice of proper medication presents a clinical dilemma between efficacy and safety. As a result, searching for comparable treatment options with safer profiles is very important. Yokukansan (TJ-54), also called yi-gan san in Chinese, is a traditional herbal medicine with evident therapeutic effect for neuropsychiatric disorders. There are several open-label clinical studies upholding the possibility of using yokukansan to treat schizophrenia or schizophrenia-like psychosis. Evidence from animal studies and neurobiology also sheds light on the antipsychotic implications of yokukansan and its ingredients. Nevertheless, correlations between the experimental environment and clinical settings may be complicated by a number of confounders. Clinical trials with more sophisticated designs are required to fill the gap between the experimental environment and clinical settings.
精神分裂症是一种使人衰弱的精神病,几乎影响到人类所有的精神功能。这种疾病的破坏性影响通常是持久的,需要终身治疗。尽管精神药理学的理解已经发展,但抗精神病药物的整体治疗效果仍然不尽如人意。在疗效和安全性之间,适当药物的选择呈现出临床困境。因此,寻找具有更安全特征的可比治疗选择非常重要。和汉三才(TJ-54),中文也称为医肝散,是一种传统的草药,对神经精神疾病有明显的疗效。有几项开放标签的临床研究支持使用和汉三才治疗精神分裂症或类似精神分裂症的精神病的可能性。来自动物研究和神经生物学的证据也揭示了和汉三才及其成分的抗精神病作用。然而,实验环境与临床环境之间的相关性可能因许多混杂因素而变得复杂。需要更复杂设计的临床试验来填补实验环境与临床环境之间的差距。